Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS).

Rao VK, Price S, Perkins K, Aldridge P, Tretler J, Davis J, Dale JK, Gill F, Hartman KR, Stork LC, Gnarra DJ, Krishnamurti L, Newburger PE, Puck J, Fleisher T.

Pediatr Blood Cancer. 2009 Jul;52(7):847-52. doi: 10.1002/pbc.21965.

2.

Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome.

Rao VK, Dugan F, Dale JK, Davis J, Tretler J, Hurley JK, Fleisher T, Puck J, Straus SE.

Br J Haematol. 2005 May;129(4):534-8.

PMID:
15877736
3.

Effect of anti-CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndrome.

Heelan BT, Tormey V, Amlot P, Payne E, Mehta A, Webster AD.

Br J Haematol. 2002 Sep;118(4):1078-81.

PMID:
12199788
4.

B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.

Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, Patriarca F, de Vita S, Regazzi M, Baccarani M, Fanin R.

Haematologica. 2002 Feb;87(2):189-95. Erratum in: Haematologica 2002 Mar;87(3):336.

5.

Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.

Osterborg A, Karlsson C, Lundin J.

Curr Hematol Malig Rep. 2009 Jan;4(1):47-53. doi: 10.1007/s11899-009-0007-4. Review.

PMID:
20425438
6.

Rituximab for the treatment of autoimmune cytopenias in children with immune deficiency.

Kim JJ, Thrasher AJ, Jones AM, Davies EG, Cale CM.

Br J Haematol. 2007 Jul;138(1):94-6. Epub 2007 May 11.

PMID:
17498197
7.

[Primary immunodeficiencies presenting with autoimmune cytopenias in adults].

Sève P, Broussolle C, Pavic M.

Rev Med Interne. 2013 Mar;34(3):148-53. doi: 10.1016/j.revmed.2012.05.007. Epub 2012 Jun 15. Review. French.

PMID:
22703729
8.

Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients.

Gobert D, Bussel JB, Cunningham-Rundles C, Galicier L, Dechartres A, Berezne A, Bonnotte B, DeRevel T, Auzary C, Jaussaud R, Larroche C, LeQuellec A, Ruivard M, Seve P, Smail A, Viallard JF, Godeau B, Hermine O, Michel M.

Br J Haematol. 2011 Nov;155(4):498-508. doi: 10.1111/j.1365-2141.2011.08880.x. Epub 2011 Oct 8.

9.

Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial.

Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT.

Blood. 2016 Jan 7;127(1):17-28. doi: 10.1182/blood-2015-07-657981. Epub 2015 Oct 26.

10.

Rituximab for the treatment of refractory autoimmune hemolytic anemia in children.

Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, Jankovic M, Pierani P, De Stefano P, Bonora MR, Locatelli F.

Blood. 2003 May 15;101(10):3857-61. Epub 2003 Jan 16.

11.

Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus.

Olfat M, Silverman ED, Levy DM.

Lupus. 2015 Aug;24(9):966-72. doi: 10.1177/0961203315578764. Epub 2015 Mar 24.

PMID:
25804672
12.

Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.

Shanafelt TD, Madueme HL, Wolf RC, Tefferi A.

Mayo Clin Proc. 2003 Nov;78(11):1340-6.

PMID:
14601692
13.

Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL/lpr-/- mice or in patients with autoimmune lymphoproliferative syndrome.

Rao VK, Dowdell KC, Dale JK, Dugan F, Pesnicak L, Bi LL, Hoffmann V, Penzak S, Avila NA, Fleisher TA, Puck JM, Straus SE.

Am J Hematol. 2007 Dec;82(12):1049-55.

14.

Mycophenolate mofetil as an alternate immunosuppressor for autoimmune lymphoproliferative syndrome.

Kossiva L, Theodoridou M, Mostrou G, Vrachnou E, Le Deist F, Rieux-Laucat F, Kanariou MG.

J Pediatr Hematol Oncol. 2006 Dec;28(12):824-6.

PMID:
17164652
15.

Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias.

Rao A, Kelly M, Musselman M, Ramadas J, Wilson D, Grossman W, Shenoy S.

Pediatr Blood Cancer. 2008 Apr;50(4):822-5.

PMID:
17570702
16.

[Role of rituximab in the management of refractory autoimmune cytopenia].

Losa Frías V, García Sánchez AM, Ortiz Valentín I, González Vicent M, Velasco Arribas MR, Madero López L, Sevilla Navarro J.

An Pediatr (Barc). 2013 Jun;78(6):398-404. doi: 10.1016/j.anpedi.2012.11.008. Epub 2012 Dec 21. Spanish.

17.

Rapid regression of lymphadenopathy upon rapamycin treatment in a child with autoimmune lymphoproliferative syndrome.

Janić MD, Brasanac CD, Janković JS, Dokmanović BL, Krstovski RN, Kraguljac Kurtović JN.

Pediatr Blood Cancer. 2009 Dec;53(6):1117-9. doi: 10.1002/pbc.22151.

PMID:
19588524
18.
19.

Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies.

Reynaud Q, Durieu I, Dutertre M, Ledochowski S, Durupt S, Michallet AS, Vital-Durand D, Lega JC.

Autoimmun Rev. 2015 Apr;14(4):304-13. doi: 10.1016/j.autrev.2014.11.014. Epub 2014 Dec 9.

PMID:
25497766
20.

Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.

Dierickx D, Verhoef G, Van Hoof A, Mineur P, Roest A, Triffet A, Kentos A, Pierre P, Boulet D, Bries G, Lê PQ, Janssens A, Delannoy A.

J Intern Med. 2009 Nov;266(5):484-91. doi: 10.1111/j.1365-2796.2009.02126.x. Epub 2009 Apr 27.

Supplemental Content

Support Center